ReviewPharmaceutical research2026
Low Analytical Evaluation Threshold in Leachables Screening: Challenges, Potential Solutions and Alternative Approaches.
Review in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Achieving the Analytical Evaluation Threshold (AET) for leachables is critical in quantification for patient safety evaluation but presents challenges for drug products with large dosing volumes or complex matrices. This paper reviews these challenges, presents industry perspectives, and proposes scientifically justified approaches to ensure patient safety where the AET is not analytically achievable. An industry-wide survey conducted by the Extractables and Leachables Safety Information Exchange (ELSIE) Consortium among 23 member companies identified common hurdles and alternative approaches used in leachables risk assessments. Findings were supplemented with case studies and a review of current analytical and regulatory strategies. The survey identified large dosing volumes (74% respondents) and matrix complexity (68% respondents) as the primary drivers for unachievable AETs. Matrix complexity was shown to significantly impact achievable limits of quantification (LOQs), with reported LOQs ranging from < 10 parts per billion (ppb) in simple aqueous solutions to > 100 ppb in complex matrices like protein-based or lipid-based formulations. Key analytical difficulties included identifying unknown leachables, background interference, and differentiating true leachables from analytical artifacts. When conventional screening methods cannot meet the AET, a robust, scientifically rationalized alternative approach is essential. Recommendations include implementing targeted leachable studies for enhanced sensitivity, using simulation studies to predict leachable profiles without matrix interference, and applying predictive modelling. For therapies addressing life-threatening conditions, a risk-benefit analysis leveraging the "less than lifetime" (LTL) concept may justify higher thresholds. Demonstrating rigorous method development efforts and providing scientific justification for the chosen strategy is crucial for regulatory alignment and ensuring patient safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.